The Indian Supreme Court has rejected Novartis' patent application for its anti-cancer drug Glivec (imatinib mesylate) saying that “application for patent on the beta-crystalline salt does not meet any standard of novelty or ...
Tags: Indian Apex, Novartis'Patent Plea, Glivec